Valuation: Conavi Medical Corp.

Market Cap 22.25M 15.65M 13.71M 12.62M 11.72M 1.49B 22.55M 151M 58.81M 733M 58.77M 57.48M 2.54B P/E 2024 *
-
P/E 2025 -1.88x
Enterprise Value 36.32M 25.54M 22.37M 20.6M 19.12M 2.44B 36.81M 247M 95.98M 1.2B 95.92M 93.81M 4.15B EV / Sales 2024 *
-
EV / Sales 2025 7.18x
Free-Float
66.52%
Yield 2024 *
-
Yield 2025 -
1 day-12.45%
1 week-10.51%
Current month-4.43%
1 month-10.00%
3 months-45.86%
6 months-56.77%
Current year-52.34%
1 week 0.15
Extreme 0.1536
0.18
1 month 0.15
Extreme 0.1457
0.2
Current year 0.15
Extreme 0.1457
0.43
1 year 0.15
Extreme 0.1457
0.56
3 years 0
Extreme 0.0007
1
5 years 0
Extreme 0.0007
1
10 years 0
Extreme 0.0007
1
Change 5-day change 1-year change 3-year change Capi.($)
-12.45%-10.51% - - 15.65M
-1.12%+2.21%+20.56%+0.05% 192B
+1.60%+6.62%-20.50%+31.10% 153B
-2.18%+0.44%-4.71%-17.40% 137B
-1.20%+2.58%-57.25%-15.66% 66.29B
+0.86%+4.39%+23.95%+5.22% 54.8B
-0.26%+2.41%-25.36%-29.38% 44.44B
-0.11%+2.72%+8.19%+42.98% 37.2B
-0.07%-1.68%+7.60%+10.28% 36.89B
+4.18%+10.06%-15.01%+1.58% 31.5B
Average -1.06%+3.01%-6.95%+3.20% 83.76B
Weighted average by Cap. -0.24%+3.29%-4.42%+3.14%

Financials

2024 2025
Net sales 2.16M 1.52M 1.33M 1.23M 1.14M 145M 2.19M 14.68M 5.71M 71.16M 5.71M 5.58M 247M 9.12M 6.42M 5.62M 5.18M 4.8M 612M 9.25M 61.95M 24.11M 300M 24.09M 23.56M 1.04B
Net income -43.62M -30.67M -26.86M -24.74M -22.97M -2.93B -44.2M -296M -115M -1.44B -115M -113M -4.98B -20.52M -14.43M -12.64M -11.64M -10.8M -1.38B -20.79M -139M -54.22M -676M -54.19M -53M -2.34B
Net Debt 82.74M 58.19M 50.96M 46.94M 43.57M 5.55B 83.86M 562M 219M 2.72B 219M 214M 9.45B 14.06M 9.89M 8.66M 7.98M 7.41M 944M 14.26M 95.52M 37.17M 463M 37.15M 36.33M 1.61B
Logo Conavi Medical Corp.
Conavi Medical Corp. is a Canada-based medical device company. The Company is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. The Novasight Hybrid System is intended for intravascular imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. Its Novasight Hybrid System combines both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. Hybrid IVUS and OCT imaging provides additional information over single modality imaging in complex lesions. The versatility of hybrid imaging is useful for a variety of complex percutaneous coronary interventions (PCIs), including situations where the customer may want to image large ostial lesions with IVUS but also use OCT for diseased distal lesions and/or stent assessment.
Employees
-
Date Price Change Volume
26-07-06 US$0.1575 -12.45% 19,477
26-07-01 US$0.1799 +9.16% 1,352
26-06-30 US$0.1648 -6.36% 55,039

Annual profits - Rate of surprise